Low CD4 + T cell count is related to specific anti-nuclear antibodies, IFNα protein positivity and disease activity in systemic lupus erythematosus pregnancy.

"Declarations Ethical approval and consent to participateThe study complies with the Declaration of Helsinki and was approved by the appropriate medical ethical committee, the regional ethics committee of Gothenburg (Dnr 404–18 and amendment Dnr 2020–05101 and Dnr 2022–01158-02). All participants signed an informed consent form. Consent for publicationNot applicable. Competing interestsHZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. LR has collaboration with Astra Zeneca, Bristol Myers Squibb (BMS), AMPEL Biosolutions, UCB and Bayer. ES has received a research grant from Merck and lecture honoraria from Janssen. The other authors declare no conflict of interest. Competing interests HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. LR has collaboration with Astra Zeneca, Bristol Myers Squibb (BMS), AMPEL Biosolutions, UCB and Bayer. ES has received a research grant from Merck and lecture honoraria from Janssen. The other authors declare no conflict of interest."

"Funding Open access funding provided by University of Gothenburg. This study was supported by grants from the Swedish Research Council; the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement; foundations of The King Gustaf V’s 80th Birthday found; the Swedish Rheumatism Association; the Gothenburg Society of Medicine; foundations of Ulla and Roland Gustafsson, Nanna Svartz, Rune and Ulla Amlöv, Hjalmar Svensson, IngaBritt and Arne Lundberg, Ingegerd Johansson and Emil and Wera Cornell; The Swedish Society of Medicine."